DTU Logo
Publications | Conference abstracts | Slidesets | Webcasts

Publications (14 of 421)


Search Publications :

In-press or Epub

What does the ACE trial tell us? – Commentary
Rury R. Holman
Journal of Diabetes 2018. Epub:17-May-2018. PMID:29774661. doi:10.1111/1753-0407.12770

Genetic Variants in CPA6 and PRPF31 are Associated with Variation in Response to Metformin in Individuals with Type 2 Diabetes
Rotroff DM, Yee SW, Zhou K, Marvel SW, Shah HS, Jack JR, Havener TM, Hedderson MM, Kubo M, Herman MA, Gao H, Mychaleckyi JC, McLeod HL, Doria A, Giacomini KM, Pearson ER, Wagner MJ, Buse JB, Motsinger-Reif AA; MetGen Investigators and the ACCORD/ACCORDion Investigators.
Diabetes 2018. Epub:12-Apr-2018. PMID:29650774. doi:10.2337/db17-1164

Effect of race on the glycaemic response to sitagliptin. Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
Davis TME, Mulder H, Lokhnygina Y, Standl E, Aschner P, Chuang LM, Grado CR, Peterson ED, Holman RR
Diabetes, Obesity and Metabolism 2018. Epub:06-Feb-2018. PMID:29405540. doi:10.1111/dom.13242

2018

Longitudinal Medical Resources and Costs Among Type 2 Diabetes Patients Participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
Reed SD, Li Y, Leal J, Graham F, Radican L, Adler A, Alfredsson J, Buse JB, Green JB, Kaufman KD, Riefflin A, Van de Werf F, Peterson ED, Gray AM, Holman RR, TECOS Study Group
Diabetes Obes Metab 2018;20:1732-1739. Published:Jul-2018. Epub:23-Mar-2018. PMID:29573215. doi:10.1111/dom.13292

Aspects of Multicomponent Integrated Care Promote Sustained Improvement in Surrogate Clinical Outcomes: A Systematic Review and Meta-analysis
Lee-Ling Lim, Eric S.H. Lau, Alice P.S. Kong, Melanie J. Davies, Naomi S. Levitt, Björn Eliasson, Carlos A. Aguilar-Salinas, Guang Ning, Yutaka Seino, Wing-Yee So, Margaret McGill, Graham D. Ogle, Trevor J. Orchard, Philip Clarke, Rury R. Holman, Edward W. Gregg, Juan José Gagliardino, Juliana C.N. Chan
Diabetes Care 2018;41:1312-1320. Published:Jun-2018. PMID:29784698. doi:10.2337/dc17-2010

A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks
Matthew C. Riddle, Hertzel C. Gerstein, Rury R. Holman, Silvio Inzucchi, Bernard Zinman, Sophia Zoungas, and William T. Cefalu
Diabetes Care 2018;41:1121-1124. Published:Jun-2018. PMID:29784695. doi:10.2337/dci18-0018

Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT
Simon J Griffin, M Angelyn Bethel, Rury R Holman, Kamlesh Khunti, Nicholas Wareham, Gwen Brierley, Melanie Davies, Andrew Dymond, Rose Eichenberger, Philip Evans, Alastair Gray, Colin Greaves, Kyla Harrington, Graham Hitman, Greg Irving, Sarah Lessels, Ann Millward, John R Petrie, Martin Rutter, Mike Sampson, Naveed Sattar and Stephen Sharp
Health Technology Assessment 2018;22:1-64. Published:Apr-2018. PMID:29652246. doi:10.3310/hta22180 M

Class Effect for SGLT2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist
Bethel MA, McMurray JJV
Circulation 2018;137:1218-1220. Published:20-Mar-2018. PMID:29555706. doi:10.1161/CIRCULATIONAHA.117.030117

Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data
Kunal N. Karmali, Donald M. Lloyd-Jones, Joep van der Leeuw, David C. Goff, Jr., Salim Yusuf, Alberto Zanchetti, Paul Glasziou, Rodney Jackson, Mark Woodward, Anthony Rodgers, Bruce C. Neal, Eivind Berge, Koon Teo, Barry R. Davis, John Chalmers, Carl Pepine, Kazem Rahimi, Johan SundstroÈm, on behalf of the Blood Pressure Lowering Treatment Trialists' Collaboration
PloS Med 2018;15:e100253. Published:20-Mar-2018. PMID:29558462. doi:10.1371/journal.pmed.1002538

Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype
Eberhard Standl, Susanna R. Stevens, Paul W. Armstrong, John B. Buse, Juliana C.N. Chan, Jennifer B. Green, John M. Lachin, Andre Scheen, Florence Travert, Frans Van de Werf, Eric D. Peterson, and Rury R. Holman, on behalf of the TECOS Study Group
Diabetes Care 2018;41:596-603. Published:Mar-2018. Epub:08-Jan-2018. PMID:29311155. doi:10.2337/dc17-1778

Management of T2DM in 2017: Clinically relevant results from cardiovascular outcome trials
Rury R Holman
Nature Reviews Endocrinology 2018;14:67-68. Published:Feb-2018. Epub:05-Jan-2018. PMID:29302077. doi:10.1038/nrendo.2017.179

Modelling incremental benefits on complications rates when targeting lower HbA1c levels in people with Type 2 diabetes and cardiovascular disease
S. A. Mostafa, R. L. Coleman, O. F. Agbaje, A. M. Gray, R. R. Holman and M. A. Bethel
Diabet Med. 2018;35:72-77. Published:Jan-2018. Epub:23-Oct-2017. PMID:29057545. doi:10.1111/dme.13533

Cardiovascular Outcomes Trials in Type 2 Diabetes:Where Do We Go From Here? Reflections From a Diabetes Care Editors’ Expert Forum
William T. Cefalu, Sanjay Kaul, Hertzel C. Gerstein, Rury R. Holman, Bernard Zinman, Jay S. Skyler, Jennifer B. Green, John B. Buse, Silvio E. Inzucchi, Lawrence A. Leiter, Itamar Raz, Julio Rosenstock, and Matthew C. Riddle
Diabetes Care 2018;41:14-31. Published:Jan-2018. PMID:29263194. doi:10.2337/dci17-0057

Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long- Term Glycemic Response to DPP-4 Inhibitor Therapy
John M. Dennis, Beverley M. Shields, Anita V. Hill, Bridget A. Knight, Timothy J. McDonald, Lauren R. Rodgers, Michael N. Weedon, William E. Henley, Naveed Sattar, Rury R. Holman, Ewan R. Pearson, Andrew T. Hattersley, and Angus G. Jones, on behalf of the MASTERMIND consortium
Diabetes Care 2018;41:705-712. Epub:31-Jan-2018. PMID:29386249. doi:10.2337/dc17-1827